Twist Bioscience (NASDAQ:TWST) Trading Down 3.7% - Should You Sell?

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) fell 3.7% during mid-day trading on Tuesday . The stock traded as low as $50.61 and last traded at $50.78. 257,980 shares were traded during mid-day trading, a decline of 65% from the average session volume of 747,018 shares. The stock had previously closed at $52.75.

Analyst Ratings Changes

TWST has been the topic of a number of research analyst reports. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday. Finally, TD Cowen reaffirmed a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.80.

Twist Bioscience Trading Down 2.6 %

The stock's fifty day simple moving average is $48.91 and its two-hundred day simple moving average is $46.20. The firm has a market cap of $3.12 billion, a PE ratio of -15.47 and a beta of 1.87. The company has a quick ratio of 4.54, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.75) EPS. On average, sell-side analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 5,886 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Patrick John Finn sold 10,340 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the completion of the sale, the chief operating officer now owns 221,061 shares of the company's stock, valued at $10,610,928. The trade was a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,002 shares of company stock valued at $2,851,681. Insiders own 3.01% of the company's stock.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its stake in shares of Twist Bioscience by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company's stock worth $1,531,000 after buying an additional 1,104 shares during the last quarter. SG Americas Securities LLC boosted its position in Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company's stock worth $495,000 after purchasing an additional 8,797 shares during the last quarter. CWM LLC grew its stake in shares of Twist Bioscience by 141.9% during the 3rd quarter. CWM LLC now owns 5,894 shares of the company's stock valued at $266,000 after purchasing an additional 3,457 shares during the period. Exchange Traded Concepts LLC increased its position in shares of Twist Bioscience by 30.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company's stock valued at $910,000 after purchasing an additional 4,661 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Twist Bioscience by 30.7% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 10,658 shares of the company's stock worth $482,000 after purchasing an additional 2,505 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.